146 results on '"van Putten, Maaike"'
Search Results
2. The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model
3. Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling
4. Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model
5. Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
6. Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model
7. Voluntary exercise improves muscle function and does not exacerbate muscle and heart pathology in aged Duchenne muscular dystrophy mice
8. Diffusion‐tensor magnetic resonance imaging captures increased skeletal muscle fibre diameters in Becker muscular dystrophy
9. Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy
10. Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes
11. On the use of D2.B10-Dmdmdx/J (D2.mdx) Versus C57BL/10ScSn-Dmdmdx/J (mdx) Mouse Models for Preclinical Studies on Duchenne Muscular Dystrophy: A Cautionary Note from Members of the TREAT-NMD Advisory Committee on Therapeutics
12. Sexual Dimorphism in Transcriptional and Functional Glucocorticoid Effects on Mouse Skeletal Muscle
13. The predictive value of models of neuromuscular disorders to potentiate clinical translation
14. Sexual Dimorphism in Transcriptional and Functional Glucocorticoid Effects on Mouse Skeletal Muscle
15. Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
16. The therapeutic potential of soluble activin type receptor IIB treatment in a limb girdle muscular dystrophy type 2D mouse model
17. On the use of D2.B10-Dmdmdx/J (D2.mdx) Versus C57BL/10ScSn-Dmdmdx/J (mdx) Mouse Models for Preclinical Studies on Duchenne Muscular Dystrophy: A Cautionary Note from Members of the TREAT-NMD Advisory Committee on Therapeutics.
18. Efficient Downregulation of Alk4in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy
19. Referee report. For: Identification of quantitative polymerase chain reaction reference genes suitable for normalising gene expression in the brain of normal and dystrophic mice and dogs [version 1; peer review: 1 approved with reservations]
20. Sexual Dimorphism in Transcriptional and Functional Glucocorticoid Effects on Mouse Skeletal Muscle.
21. Asymmetrical myofiber architecture along the murine tibialis anterior suggests distinct functional regions
22. 'Of Mice and Measures': A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic
23. A data-driven methodology reveals novel myofiber clusters in older human muscles
24. Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
25. Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model
26. A data‐driven methodology reveals novel myofiber clusters in older human muscles
27. Mouse models for muscular dystrophies: an overview
28. Moving neuromuscular disorders research forward: from novel models to clinical studies
29. Asymmetrical myofiber architecture along the murine tibialis anterior suggests distinct functional regions
30. Discovering fiber type architecture over the entire muscle using data‐driven analysis.
31. The use of genetically humanized animal models for personalized medicine approaches
32. 240th ENMC workshop: The involvement of skeletal muscle stem cells in the pathology of muscular dystrophies 25–27 January 2019, Hoofddorp, The Netherlands
33. Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F
34. A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
35. Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
36. High-throughput data-driven analysis of myofiber composition reveals muscle-specific disease and age-associated patterns
37. Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
38. Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands
39. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
40. 227 th ENMC International Workshop
41. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
42. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
43. Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy.
44. High-throughput data-driven analysis of myofiber composition reveals muscle-specific disease and age-associated patterns.
45. Environmental 24-hr Cycles Are Essential for Health
46. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models
47. PABPN1-Dependent mRNA Processing Induces Muscle Wasting
48. Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods
49. Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9
50. Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.